首页 | 本学科首页   官方微博 | 高级检索  
检索        

环孢素血药浓度水平对重型再生障碍性贫血患者免疫抑制治疗近期疗效的影响
作者姓名:Liang LY  Zhang L  Jing LP  Zhou K  Wang XD  Li Y  Peng GX  Li Y  Li JP  Shi LH  Ye L  Fan HH  Zhang P  Chu YL  Zhang FK
作者单位:1. 苏州大学附属第二医院工作,215004
2. 中国医学科学院、北京协和医学院血液学研究所、血液病医院,天津,300020
摘    要:目的 研究环孢素(CsA)血药浓度水平是否影响重型和(或)极重型再生障碍性贫血(SAA/VSAA)患者免疫抑制治疗(IST)早期疗效,探讨CsA的合理使用方法.方法 回顾性分析兔源抗胸腺细胞球蛋白(r-ATG)联合CsA方案初始治疗的90例SAA/VSAA患者临床资料,分别比较IST后6个月获得治疗反应和未获治疗反应患者间CsA血药浓度水平的差异,以及不同CsA血药浓度对SAA/VSAA患者获得治疗反应的影响.结果 ①初始CsA血药浓度对SAA/VSAA患者近期IST疗效无影响,但与SAA患者更早获得治疗反应相关;②获得治疗反应组患者IST第3个月CsA谷值血药浓度(C0)和峰值血药浓度(C2)均较未获治疗反应组患者明显增高(P值分别为0.024和0.009),IST其他时间段CsA血药浓度平均水平两组间差异无统计学意义(P>0.05).③IST第3个月C0≥200 μg/L组患者治疗反应率为82.4%,明显高于C0 150~200μg/L组的55.6% (P =0.023)和C0<150 μg/L组的59.3% (P =0.046);IST第3个月C2≥700 μg/L组患者治疗反应率为80.5%,明显高于C2 <700 μg/L组的55.3% (P =0.012).结论 CsA血药浓度水平影响SAA/VSAA患者近期疗效;IST第3个月CsA血药浓度水平对患者获得早期疗效尤为重要,维持CsA血药浓度C0≥200 μg/L、G2≥700 μg/L或可进一步提高SAA/VSAA患者IST治疗反应率.

关 键 词:环孢素  药物监测  贫血  再生障碍性  治疗结果

Effects of concentration of cyclosporine A on the early response to immunosuppressive therapy in severe aplastic anemia
Liang LY,Zhang L,Jing LP,Zhou K,Wang XD,Li Y,Peng GX,Li Y,Li JP,Shi LH,Ye L,Fan HH,Zhang P,Chu YL,Zhang FK.Effects of concentration of cyclosporine A on the early response to immunosuppressive therapy in severe aplastic anemia[J].Chinese Journal of Hematology,2011,32(11):766-771.
Authors:Liang Li-yan  Zhang Li  Jing Li-ping  Zhou Kang  Wang Xiao-dan  Li Yang  Peng Guang-xin  Li Yuan  Li Jian-ping  Shi Li-Hui  Ye Lei  Fan Hui-hui  Zhang Ping  Chu Yu-lin  Zhang Feng-kui
Institution:Institute of Hematology and Blood Diseases Hospital, Tianjin, China.
Abstract:Objective To evaluate the effects of cyclosporine A (CsA) whole-blood concentration on the early response to immunosuppressive therapy (IST) in severe and very severe aplastic anemia ( SAA/ VSAA).Methods Ninety SAA/VSAA patients treated with rabbit antithymocyte globulin (ATG) plus CsA as first line therapy in our hospital were retrospectively analysed.CsA levels between the response group and non-response group,and response rates of patients with variant CsA levels were compared respectively.Results ①There was no significant difference in the beginning unmodified CsA blood concentration between IST responded and non-responded SAA/VSAA patients.The beginning unmodified Co 133.91 ug/L in IST 2-month responders was higher than that of 49.9 ug/L in non-responded SAA patients ( P =0.009 ) ; ②The mean CsA Co and C2 levels during the third month following IST were significantly different in responders and non-responders ( 197.52 μg/L vs 161.49 μg/L,P =0.024,and 738.76 μg/L vs 615.46 μg/L,P =0.009 ),and no significant difference in other periods of IST(P>0.05) ; ③The response rate (87.5%) was significantly higher in patients with CsA C0 ≥200μg/L the third month following IST than those of 55.6% in patients with CsA Co 150 -200 μg/L(P =0.023) and 59.3% in patients with CsA C0 < 150 μg/L(P =0.046),respectively.The response rate was significantly higher of C2 ≥700 μg/L group than that of C2 <700 μg/L group( 80.5% vs 55.3%,P =0.012).Conclusions The CsA concentration related to the early IST response.The third month CsA concentrations was the most important for the response and maintaining CsA levels with Co ≥200 μg/L and C2 ≥700 μg/L may improve the response to IST in SAA/VSAA.
Keywords:Cyclosporine A  Blood concentration monitoring  Anemia  aplastic  Outcome
本文献已被 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号